OVERVIEW
Neuro-Oncology
TOPICS
Key Discussion Areas
Core scientific themes explored across all sessions in this track.
Interventional Cardiology Advances
Latest techniques in percutaneous coronary intervention, transcatheter structural interventions, and complex bifurcation stenting with outcome data from 2025–2026 trials.
Heart Failure: New Drug Classes
Comprehensive review of SGLT2 inhibitors across HFrEF/HFpEF, mavacamten in HCM, and emerging agents in the pipeline with mechanisms and clinical trial evidence.
AI in Cardiac Imaging
Clinical validation data for AI tools in echocardiography, cardiac MRI, and CT angiography — including automated ejection fraction, plaque characterisation, and anomaly detection.
Cardiac Genetics & Cardiomyopathy
CRISPR applications in hereditary cardiomyopathy, genotype-guided risk stratification, and family screening protocols in hypertrophic and dilated cardiomyopathies.
Arrhythmia & Electrophysiology
Catheter ablation advances in persistent AF, ventricular tachycardia, and SCA prevention strategies including novel antiarrhythmic drug data and wearable monitoring.
Preventive Cardiology
Polygenic risk scores in cardiovascular prevention, novel lipid-lowering strategies beyond statins, and population health approaches to primary cardiovascular prevention.
AUDIENCE
Who Should Attend?
This track is designed for clinicians, researchers, and allied health professionals with an interest in neuro-oncology.
- Cardiologists and cardiology trainees
- Interventional cardiologists
- Cardiac electrophysiologists
- Heart failure specialists
- Cardiothoracic surgeons
- Clinical cardiac physiologists
- Internal medicine physicians with cardiovascular interest
- Cardiovascular nurses and allied health professionals
- Cardiovascular researchers and clinical trialists
Attend Neuro-Oncology
Join delegates from 120+ countries for three days of world-class clinical science at the Healthcore Bridge International Medical Conference 2026.
FAQs
Frequently Asked Questions
What is the scope of the Oncology & Haematology track?
The Oncology & Haematology track covers precision oncology, immunotherapy, ADC therapies, haematological malignancies, liquid biopsy and early detection, AI in oncology, and palliative care — across 22 sessions over three conference days. It is the largest scientific track at the 2026 conference.
Will there be separate sessions for haematology and solid tumours?
Yes. The track is structured with dedicated morning sessions for haematological malignancies and afternoon sessions focusing on solid tumour oncology. The final panel each day brings all specialties together for cross-disciplinary discussion.
Are there oncology workshops available?
Yes. Two hands-on workshops complement the oncology track: a molecular tumour board simulation workshop and an AI pathology interpretation masterclass. Both require separate registration due to a 30-delegate capacity limit.
Is this track accredited for oncology-specific CME?
All oncology sessions are accredited for CME under EACCME, AMA PRA Category 1, and the Royal College of Radiologists (for radiation oncologists). Specialty-specific CME credit allocation is detailed in the conference programme and the CME pre-event delegate guide.